The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC).
Lee Steven Schwartzberg
Consultant or Advisory Role - Amgen
Fernando Rivera
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Meinolf Karthaus
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Gianpiero Fasola
Consultant or Advisory Role - Amgen
Jean-Luc Canon
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Expert Testimony - Amgen
Hua Yu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen